ArticleFrontiers in veterinary science2026
The scorpion peptide Eval418 inhibits duck Tembusu virus replication by disrupting viral structure and early-stage infection.
Article in Frontiers in veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Duck Tembusu virus (DTMUV) causes egg-drop syndrome and neurological symptoms in ducks, resulting in significant economic losses. Currently, no specific antiviral drugs are available for DTMUV infection. Scorpion-derived peptides have emerged as promising lead compounds for antiviral drug development. In this study, we investigated the antiviral activity and mechanism of the scorpion peptide Eval418 against DTMUV infection Methods: DF-1 cells were infected with DTMUV at an MOI of 0.1 and treated with Eval418 (0-20 μM), with Ribavirin as a positive control. Antiviral activity was assessed by Western blot, RT-qPCR, and immunofluorescence assays targeting the DTMUV NS3 protein. Cytotoxicity and hemolytic activity were evaluated in DF-1, DEF, chicken and duck red blood cells the influence of duck serum on Eval418 was examined. Time-of-addition, free virion, attachment, and entry/fusion assays were performed, along with transmission electron microscopy and molecular docking/MD simulations of the NS3-Eval418 complex. Results: Eval418 inhibited DTMUV replication in a concentration-dependent manner, achieving over 99% inhibition at 10 μM, with no significant cytotoxicity or hemolytic activity up to 120 μM in all tested cells. Mechanistic studies revealed that Eval418 acted primarily during the coaddition stage by directly inactivating free virions, blocking viral attachment, and inhibiting viral entry/fusion. TEM confirmed that Eval418 directly disrupted the morphological integrity of DTMUV virions, causing structural collapse. MD simulations showed that Eval418 binds stably to the NS3 binding pocket. Eval418 also inhibited two genetically distinct DTMUV isolates, whereas prolonged incubation with duck serum progressively reduced its antiviral activity. Conclusion: These findings establish Eval418 as a promising lead compound for the development of antiviral therapeutics against DTMUV infection as a model flavivirus. Its potential efficacy against other flaviviruses requires further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.